4/23
12:03 pm
kytx
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet [CNBC]
Low
Report
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet [CNBC]
4/11
05:10 pm
kytx
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases [Yahoo! Finance]
Low
Report
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases [Yahoo! Finance]
4/11
05:01 pm
kytx
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Low
Report
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
4/8
02:19 am
kytx
ViroCell to present at 2024 Cell & Gene Meeting on the Med [Yahoo! Finance]
Medium
Report
ViroCell to present at 2024 Cell & Gene Meeting on the Med [Yahoo! Finance]
3/29
03:08 pm
kytx
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med [Yahoo! Finance]
Medium
Report
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med [Yahoo! Finance]
3/29
02:59 pm
kytx
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Medium
Report
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
3/26
04:18 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/26
04:05 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
3/7
07:33 pm
kytx
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis [Yahoo! Finance]
3/7
07:26 pm
kytx
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Medium
Report
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
3/6
07:26 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
3/4
08:56 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $48.00 price target on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $48.00 price target on the stock.
3/4
08:56 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $44.00 price target on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $44.00 price target on the stock.
3/4
08:06 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
3/4
08:06 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $39.00 price target on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $39.00 price target on the stock.
2/12
04:39 pm
kytx
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Low
Report
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
2/7
10:29 pm
kytx
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
High
Report
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering